Drugs / Cidabenamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07389616 | Feb 2026 → Feb 2028 expected | peripheral T-cell lymphoma, not otherwise specified | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cidabenamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07389616 ↗ |